Seres Therapeutics, Inc. (MCRB)
NASDAQ: MCRB · Real-Time Price · USD
7.02
-0.08 (-1.06%)
Apr 29, 2026, 10:13 AM EDT - Market open
Seres Therapeutics Revenue
In the year 2025, Seres Therapeutics had annual revenue of $789.00K. Seres Therapeutics had revenue of $438.00K in the quarter ending December 31, 2025.
Revenue (ttm)
$789.00K
Revenue Growth
n/a
P/S Ratio
86.14
Revenue / Employee
$11,955
Employees
66
Market Cap
67.25M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Fortress Biotech | 63.26M |
| ImmuCell | 27.64M |
| Immutep | 5.28M |
| MediciNova | 409.66K |
| Impact BioMedical | 32.00K |
MCRB News
- 9 days ago - Seres Therapeutics Showcases SER-155 Data and Live Biotherapeutic Insights at ESCMID Global 2026 - GlobeNewsWire
- 20 days ago - Seres Therapeutics to Present at CARB-X Investor Day - GlobeNewsWire
- 6 weeks ago - Seres Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates - GlobeNewsWire
- 2 months ago - Seres Therapeutics Transcript: Status update - Transcripts
- 2 months ago - Seres Therapeutics Announces Appointment of Richard N. Kender as Executive Chair and Interim CEO; Provides Business Updates - GlobeNewsWire
- 2 months ago - Seres Therapeutics Pauses Key Drug Study, Cuts Jobs To Save Cash - Benzinga
- 2 months ago - Seres Provides Program and Corporate Updates and Prioritizes Emerging Programs in Inflammatory & Immune Diseases - GlobeNewsWire
- 4 months ago - Seres Therapeutics Announces Publications in Nature Medicine and Journal of Infectious Diseases Highlighting Vowst™ Mechanism of Action and Supporting Broader Live Biotherapeutic Strategy - GlobeNewsWire